Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Lene Ryom
  • Jens Dilling Lundgren
  • Peter Reiss
  • Kirk, Ole
  • Matthew Law
  • Mike Ross
  • Phillip Morlat
  • Christoph Andreas Fux
  • Eric Fontas
  • Stephane De Wit
  • Antonella D'Arminio Monforte
  • Wafaa El-Sadr
  • Andrew Phillips
  • Camilla Ingrid Hatleberg
  • Caroline Sabin
  • Amanda Mocroft
  • Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group

BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.

METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).

RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD.

CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.

TidsskriftThe Journal of Infectious Diseases
Udgave nummer10
Sider (fra-til)1629-1634
Antal sider6
StatusUdgivet - 2019

ID: 237753708